Qoolabs

Qoolabs is a private biotechnology company leveraging its innovative QMAb™ platform for rapid rabbit monoclonal antibody discovery. Its core business model combines a fee-for-service custom antibody development offering with a growing catalog of pre-developed antibodies targeting infectious diseases, guinea pig immunology, and common assay reagents. The company serves the research, diagnostic, and therapeutic development sectors, positioning itself as a specialized provider of high-quality antibody reagents with advantages in speed, animal welfare, and epitope diversity. While currently in a revenue-generating stage from services and product sales, its long-term value is tied to the adoption of its platform and antibodies in downstream diagnostic and therapeutic programs.

QMAb™ (Quick Monoclonal Antibody from Blood) platform for rapid discovery of rabbit monoclonal antibodies from peripheral blood mononuclear cells (PBMCs), enabling natural pairing of chains, non-lethal animal use, and fast timelines.

Qoolabs competes in the crowded antibody discovery and production services market against large players like GenScript, Abcam services, and Bio-Rad, as well as many specialized CROs. Its primary differentiation is its rabbit-specific, non-lethal QMAb™ platform, which it positions as faster and more ethical for generating high-quality antibodies against challenging targets.